Seeking AlphaBristol-Myers: Looking To Maintain Lead In ImmunotherapySeeking AlphaThe phase 2 study with accelerated approval shows the true power of Opdivo as an immunotherapy product. Competition from KEYTRUDA will be fierce in the colorectal cancer … Continue reading
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
Genetic Literacy Project |
Muscular dystrophy in dogs reversed with gene therapy–are children next?
Genetic Literacy Project Duchenne muscular dystrophy (DMD) is the most common and, sadly, the most severe form of the debilitating genetic disorder. Now researchers have used a new gene therapy technique to restore muscle strength and stabilize the symptoms of the disorder in … |
Endpoints News |
Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients
Endpoints News Noted Jefferies’ Michael Yee recently: “First data from Phase I/II of Hemophilia A gene therapy SPK-8011 in July/Aug could establish early proof-of-concept and be a (+) catalyst. Given small no. of pts to start, key is demonstrating potential to get to … Spark Therapeutics Inc (ONCE): Showing Signs Of Making It BigSimply Wall St |